ArticleBioinformation2024
Therapeutic use of oral gastrografin in treating acute adhesive small bowel obstruction.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adhesions are a major cause of small bowel obstruction, posing significant challenges in diagnosis, treatment and prevention. Adhesive small bowel obstruction has a substantial impact on morbidity and imposes a considerable socioeconomic burden. Therefore, it is of interest to study the therapeutic use of oral gastrografin in treating acute adhesive small bowel obstruction. Acute small bowel obstruction (SBO), accounting for 6-30% of cases. Adhesions are responsible for approximately 65-75% of SBO cases, necessitating careful assessment and management. This study, conducted at Chirayu Medical College & Hospital, Bhopal, India from June 2021 to May 2022, included 87 patients with 94 episodes of adhesive SBO. Initial conservative treatment resolved 63 episodes (67.02%) within 48 hours. The remaining 31 episodes (32.98%) were subjected to a Gastrografin challenge, where 23 cases (74.2%) showed successful dye transit to the colon within 24 hours, while 8 cases (25.8%) required surgical intervention. The findings suggest the Oral Gastrografin represents a significant advancement in the conservative management of acute adhesive small bowel obstruction, offering a non-invasive, effective and safe alternative to surgery for many patients. Its integration into clinical practice can enhance patient care and improve clinical outcomes in the management of ASBO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.